Pharmacology of Adjuvant Hormonotherapy in Breast Cancer

Inclusion criteria

• Patient of more than 18 years old (menopaused or not)
• Invasive breast cancer non-metastatic locally controlled by surgery with or without radiotherapy. Previous treatment with chemotherapy is allowed including trastuzumab
• Cancer hormone-expressing ER and / or PR (> 10% tumor cells in Technical HIC)
• Having a staging exploring bone, liver, lung and showing no abnormality secondary (for sub-centimeter tumors, the staging is not necessary)
• WHO <2
• Before the initiation of adjuvant hormonal therapy (tamoxifen, anastrozole, letrozole or exemestane) and whatever the approach chosen by the investigator (5 years of tamoxifen, 5 years of anti-aromatase or sequential patterns)
• signed Consent collected before any specific procedure in the study
• Patient member in a national insurance scheme.

Exclusion criteria

• Patient previously treated for breast cancer receiving hormonal therapy with tamoxifen, anastrozole, letrozole or exemestane regardless of the scheme
• Metastatic Breast cancer
• History of another cancer diagnosed within 5 years before or uncontrolled except carcinoma in situ of cervix carcinoma, nonmelanoma skin, breast cancer (in this case, treatment with hormone therapy should be stopped for at least 6 months)
• Any other medical or psychiatric condition or laboratory abnormality severe acute or chronic making the inclusion of the patient in the study inappropriate in the opinion of the investigator
• Patient unable to follow procedures, visits, examinations described in the study
• Pregnant women or nursing mothers can not participate in the study
• Women of childbearing age must use effective contraception at study entry and up to at least three months after the end of treatment
• Patient under legal guardianship